Seattle Doctor Scores Court Win Against DEA Over Refusal to Reschedule Psilocybin

Seattle Doctor Scores Court Win Against DEA Over Refusal to Reschedule Psilocybin

Last week, a federal appeals court ruled against the U.S. Drug Enforcement Agency (DEA) in a lawsuit filed by a doctor in Washington state who sought to get psilocybin rescheduled. The U.S. Court of Appeals for the Ninth Circuit stated that the agency hadn’t explained its reasoning when it denied Dr. Sunil Aggarwal’s petition, and the court ordered the DEA to provide a more complete justification.

In its letter of denial, the DEA stated that a precondition to transferring a substance from Schedule I to II under the Controlled Substance Act was for the U.S. Food and Drug Administration (FDA) to conclude that said substance had a currently accepted medical use in the United States. The agency further noted that the FDA has yet to communicate any accepted medical use for psilocybin in treatment and added that the Controlled Substances Act required that psilocybin remain in Schedule I.

For a couple of years now, Aggarwal had been seeking ways to legally access psilocybin to administer to terminally ill cancer patients who were undergoing end-of-life care. He initially sought to acquire permission from regulators under federal and state right-to-try laws, which allow patients with terminal illnesses to try investigational drugs that hadn’t been approved for general use.  When the Drug Enforcement Administration turned down the request, Aggarwal filed a lawsuit against the agency.

Early last year, a federal appellate panel dismissed the lawsuit, declaring that the court had no jurisdiction as the DEA’s rejection did not constitute a reviewable agency action. This led Aggarwal to file a formal rescheduling petition. The Ninth Circuit court’s ruling was issued as an unpublished opinion, which means it doesn’t establish legal precedent beyond the current case.

The court’s ruling also failed to honor a request by the doctor’s lawyers to send the petition to the FDA for review, as the Department of Health and Human Services agency would have been better suited to evaluate the accepted medical use of psilocybin.

It should be noted that while the ruling doesn’t change psilocybin’s current legal status, it does keep alive the petition to reschedule said drug.

This comes as more research strengthens psilocybin’s case for legitimate medical use. For instance, in September, researchers at the Ohio State University and Johns Hopkins universities published a report that linked the use of psilocybin to persisting reductions in anxiety, depression and alcohol misuse, as well as increases in extraversion, spiritual well-being and emotional regulation.

A separate study by the American Medical Association also determined that individuals with major depression saw clinically significant sustained reductions in their symptoms following the administration of a single dose of psilocybin.

The steps that individuals such as Aggarwal are taking to ensure that policies are reformed to allow the use of psychedelics for therapeutic purposes are a good complement to the data coming out from companies such as Seelos Therapeutics Inc. (NASDAQ: SEEL) that document the therapeutic potential of hallucinogenic substances. With time, laws are likely to evolve in line with the current body of scientific data.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Red White & Bloom provides update relating to Aleafia Health and other corporate matters

Red White & Bloom provides update relating to Aleafia Health and other corporate matters

(Globe Newswire) Toronto — Red White & Bloom Brands Inc. is providing an update on matters relating to Aleafia Health Inc. and other corporate matters.

Update relating to Aleafia Health

RWB is pleased to announce that in connection with the proceedings of Aleafia Health and certain of its subsidiaries under the Companies’ Creditors Arrangement Act, the Ontario Superior Court of Justice has granted an approval and reverse vesting order in respect of the previously announced sale transactions.

The approval and vesting order is the sole authorization required by the Aleafia Group to implement the transactions provided for under the previously announced stalking horse asset purchase and share subscription agreement, as amended and restated on October 24, 2023 among RWB, Aleafia Health and certain of Aleafia Health’s subsidiaries.

Advertisement

The approval and vesting order approves the implementation of the transactions contemplated by the Amended Stalking Horse Agreement, whereby a wholly-owned subsidiary of RWB would subscribe for shares of the Aleafia purchased entities and acquire specific intellectual property owned, licensed or leased by Aleafia Health. Certain excluded assets and liabilities of the Aleafia Purchased Entities would be transferred to one or more corporations that would not be included among the Aleafia Purchased Entities at closing. RWB’s subsidiary would be the sole shareholder of the Aleafia purchased entities following closing.

The court also granted an ancillary relief order approving, among other things, (i) amendments to the debtor-in-possession term sheet to increase the DIP financing available to the Aleafia Group from $6.6 million to $8 million; and (ii) an extension to the current stay period in the Aleafia CCAA proceedings to November 30, 2023, in order to, among other things, permit the parties to complete the transactions contemplated under the Amended Stalking Horse Agreement.

The consummation of the transactions contemplated under the Amended Stalking Horse Agreement is subject to satisfaction or waiver of certain conditions set forth in the Amended Stalking Horse Agreement, including, among other things, receipt of all required regulatory approvals and the Aleafia purchased entities’ Health Canada and cannabis excise licences being in good standing and continuing in good standing and not suspended or terminated following the closing date.

The parties anticipate closing the transactions contemplated under the Amended Stalking Horse Agreement following satisfaction of the remaining conditions to closing, and in any event no later than November 22, 2023 (the outside date specified in the Amended Stalking Horse Agreement).

Share issuance in connection with asset purchase

In accordance with the policies of the Canadian Securities Exchange, the company announces that its board of directors has approved the issuance of 700,000 common shares on October 30, 2023, at a deemed price of $0.06 per share, as final consideration for an asset purchase completed by a wholly-owned subsidiary of the company. All securities issued pursuant to the asset purchase are subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance. None of the securities issued in connection with the asset purchase will be registered under the United States Securities Act of 1933, as amended, and none of them will be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Red White & Bloom provides update relating to Aleafia Health and other corporate matters

Nova Cannabis announces timing of third quarter 2023 earnings release

(CNW) Edmonton — Nova Cannabis Inc. will release its third quarter 2023 financial results for the period ended September 30, 2023, after market closes on Wednesday, November 8, 2023.

Nova will hold a conference call on Thursday, November 9, 2023, at 2 p.m. MST to discuss the third quarter 2023 financial and operational results. To participate, please follow the instructions below.

Webcast access

To access the live webcast of the call, please visit the following link:
edge.media-server.com/mmc/p/tofpdave

Advertisement

Call access

Canada/USA Toll Free: (800) 715-9871

Conference ID: 807833

Bat Guano: The Plant Superfood With A Bad Rap

Bat Guano: The Plant Superfood With A Bad Rap

The Basics: What is Guano?

Bats live in large colonies, sharing the same cave from generation to generation. As a result, masses of excrement build up within the bat roost cave, eventually breaking down into rich compost. The result is a substance we call guano.

A hand holds a pile of bat guano above a clear, plastic bag of bat guano.A hand holds a pile of bat guano above a clear, plastic bag of bat guano.

Bat guano is an organic plant superfood that encourages prolific garden growth. Guano is an excellent supplement to any organic grow, indoors or out.

The History of Guano

Guano has a history as one of the most precious fertilizers in the world. It has been a respected fertilizer used by the Incas and older South American cultures for centuries. It was so vital that Incan rulers split the guano-bearing islands among the provinces.

In the early to mid-1800s, guano caused a stir in European and American farmers. A horticultural boom caused worry that the soil might be drained of nutrients irreparably until farmers saw guano’s benefits. From 1840 onwards, Britain imported upwards of two million tonnes of guano, and the administration of the United States made it a case of agricultural need.

“Guano has become so desirable to agricultural interests in the US that the Government must employ all means properly in its power to cause it to be imported into the country at a reasonable price” – US President Millard Fillmore 1850-1853

Guano was so precious to crop development that huge battles were fought over guano mines for centuries. In the 19th century, guano caused mass hysteria similar to the California gold rush. Over 40 years, Peru shipped over 20 million tonnes of guano worldwide, making over $2 billion in profit.

How Does Species Affect Guano?

The diet of various bat species can change the nutrient profile of the guano. For example, bats that eat insects produce guano with a higher nitrogen content, creating an excellent fertilizer for the vegetative stage. In contrast, fruit-eating bat varieties have guano with a higher phosphorus content, which is more valuable during the flowering stage.

What About Sustainability?

Bat guano mining can affect the biodiversity of the bat’s roost cave environment. Naturally, the guano sustains many cave-dwelling invertebrate species, which depend on it for survival. However, the most consequential damage is to the bat colonies themselves. Bats are very susceptible to any disturbance of their roosts. Analysis has indicated that bat guano mining is linked to the loss of specific bat species and associated invertebrates and fungi. Therefore, collecting guano in some regions is outlawed.

A large collection of bats glide across a spooky night sky.

A large collection of bats glide across a spooky night sky.

Unfortunately, this can sometimes lead to illegal harvesting in challenging circumstances. People will collect from remote spots, sometimes in dangerous landscapes. Miners also face health risks of repetitive exposure to bat feces without adequate safety equipment, which can cause severe respiratory problems.

Some have turned their backs on guano based on these sustainability and exploitation issues. However, some reputable companies offer organic guano fertilizer with ethics and sustainability in mind. In areas where harvesting is legal, guano collection is often government-controlled and monitored to ensure the ecosystem is not disturbed. Miners safely scoop the guano up without destroying the caves and the habitat of the bats.

The Nutritional Value of Guano

Guano is rich in nitrogen, phosphorus, and potassium (NPK), essential for plant growth. It also contains several micronutrients, including boron (B), calcium (Ca), iron (Fe), manganese (Mn), sulfur (S), zinc (Zn), and magnesium (Mg).

The Many Benefits of Guano

Guano works well in both indoor and outdoor grows. It improves soil texture by binding the soil and increasing water retention if it is too loose. In contrast, it can also loosen the earth and allow water to penetrate if it is too dense.

Guano is great for bioremediation; it helps flush toxins from the soil while protecting the roots and feeding the plant. In addition, it encourages the breakdown of other organic materials as a slow-release fertilizer, delivering nutrients to the garden long-term and adding beneficial enzymes and microflora for continued soil health. Bat guano contains varying levels of NPK. Combine them with other organic products to create individual macronutrient ratios.

A shovel digs into a mound of bat guano.

A shovel digs into a mound of bat guano.

Guano acts as a pH adjuster, buffering the pH of the root system and helping to control nematodes. In addition, it acts as a natural fungicide against chitin from insect shells and as a soil conditioner. Combine it with other organic additions, like worm castings and bone meal, to build prosperous colonies of root fauna. Finally, it offers fungal protection when used as a diluted foliar spray.

How To Use Bat Guano

Guano is the perfect foundation for any soil recipe; it will not burn your plants, and the crops you grow will be more flavourful and invulnerable to disease.

Water guano straight into your grow media. Use one tablespoon of guano per liter of warm (not hot) water. Stir together and leave to rest overnight, then apply to the garden once a week.

You can also add guano directly as a soil amendment to boost plant performance. Dig it into the earth and water well to activate it. If you sprinkle it on the surface, it will dry out, clump up, and be ineffective.

To make a nutritionally-rich compost tea:

  1. Add one teaspoon of blackstrap molasses, five tablespoons of bat guano, and 65g of fully finished compost to a 5-litre bucket of non-chlorinated water, complete with an air stone.
  2. Stir thoroughly and leave to aerate for 48 hours so aerobic beneficial microbes can populate the sugars of this nutrient-rich solution.
  3. Dilute 1 part compost tea to 10 parts water and apply a foliar spray or soil drench.

As bat guano is a rich and natural organic matter, the microbes in the soil must break it down into a soluble form for the plant roots to take up. This process typically takes around two weeks, so you shouldn’t expect to see results instantly.

Bat Guano – The Dangers

While bat guano is a true wonder regarding soil and plant health, you should be mindful that bats carry infectious diseases. In the current post-COVID environment, people are more cautious than ever.

Bat guano can damage your lungs and cause diseases like histoplasmosis. Symptoms include fever, cough, and fatigue. Many people get better without medication. However, those with weakened immune systems can experience a more severe infection.

A sachet of bat guano with a batman symbol, on a black background.

A sachet of bat guano with a batman symbol, on a black background.

Working with bat droppings requires the use of a HEPA filter mask. Attempting to work in an area where bat droppings are present may release spores into the air. Without the proper protection, this could lead to severe health consequences. Also, wearing a mask when handling or mixing bat guano into water is essential. Always clean surfaces and equipment after use and wash your hands.

Finally, leaving bat guano preparations to sit will cause harmful bacteria to develop, so use it immediately. Temperature can also have a negative effect, so keep your powdered product out of sunlight and off cold floors. Of course, you should also keep guano out of the reach of children.

Final Word

Bat guano is an excellent organic fertilizer that has been used for thousands of years, so if you want to see great results from your plants, you should try it!

Cannabis sales continue to grow across Canada, except for Manitoba

Cannabis sales continue to grow across Canada, except for Manitoba

Cannabis sales continue to grow across Canada, except for Manitoba | StratCann

Thanks to our sponsors for supporting StratCann’s work!

Cannabis sales continue to grow across Canada, except for Manitoba

Cannabis sales continue to climb in Canada, with more than $460 million sold by the 3,600+ cannabis retailers nationwide. 

Total retail sales of cannabis in August 2023 were over $464.2 million, up from about $390 million in August 2022. From July to August, sales increased in every province except for Manitoba, which saw a slight decline to pre-March 2023 levels. (This is possibly due to lower data quality for the Keystone Province’s figures for August, which Statistics Canada rates at a lower quality than those figures available for previous months.)

Like many retail sectors, cannabis sales have dipped in the months following the Christmas shopping seasons over the last three years before building again on an ongoing, upward trend. 

The number of retail stores across Canada also continues to grow, although the pace has slowed considerably compared to the first four years of legalization. As of October 2023, there were 3,640 cannabis stores in Canada, excluding provincial online stores.

  • British Columbia: 508 public and private stores either open or “coming soon”
  • Alberta: 748
  • Saskatchewan: 176
  • Manitoba: 192, 110 of which are in Winnipeg 
  • Ontario: 1,765 as authorized to open 
  • Quebec: 98
  • New Brunswick: 25 public stores, plus six private stores and six farmgate stores for a total of 37
  • Nova Scotia: 49
  • PEI: 4 
  • Newfoundland and Labrador: 49
  • Northwest Territories: 6 brick-and-mortar locations, plus 1 private online store
  • Nunavut: 1
  • Yukon: 6

Related Articles


Insight & News

Browse Categories

Thanks to our sponsors supporting StratCann’s work!
Recent Articles

SUPPORT INDEPENDENT MEDIA

If you’d like to support independent cannabis industry media, we have a simple way you can donate to our work!!

ADVERTISE WITH US

Put your business, brand and expertise in front of the Canadian cannabis industry.

Are you of legal age in your jurisdiction?
By clicking “Enter” you are verifying you are of legal age to view the content of this website, or click “Exit” to leave.


Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn

image
  • Lexaria, a global innovator in drug delivery platforms, just announced an exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology
  • Lexaria will also perform specific DehydraTECH-related manufacturing operations on SulfoSyn’s behalf for an initial term of 2 years
  • The license agreement adds to Lexaria’s growing list, which, as of the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8, LLC, among others
  • It highlights the superiority of Lexaria’s technology, as further compounded by the 37 patents granted so far

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest global, exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology. This license will allow SulfoSyn to use Lexaria’s technology in non-pharmaceutical uses of sulforaphane worldwide, with the ability to sub-license its rights to other companies (https://cnw.fm/O8yxc).

This agreement is the product of months of research for the two entities. In late 2022, both Lexaria and SulfoSyn started exploring the applicability of DehydraTECH upon sulforaphane. This Sulphur-rich composite molecule is commonly found in vegetables such as broccoli, kale, and cabbage. The testing established that DehydraTECH did have certain superior qualities on the sulforaphane molecule, a result that showed the technology’s commercial viability, specifically for SulfoSyn.

As a result, SulfoSyn will be at liberty to use the DehydraTECH technology for various non-pharmaceutical uses, including supplements, foods, additives, dietary ingredients, and more. In addition, Lexaria has also been contracted by the company to perform specific DehydraTECH-related manufacturing operations on behalf of SulfoSyn for an initial term of 2 years, an engagement that will see Lexaria increase its revenue.

An up-front cash payment has since been paid by SulfoSyn, with minimum future payments already agreed to. In addition, the licensing agreement will see an ongoing royalty payment generated once the minimum payments are exceeded.

This license agreement with SulfoSyn adds to Lexaria’s growing list, which, in the last two years, includes BevNology LLC, Premier Wellness Science Co. Ltd., and Dehydr8, LLC, among others. Given the company’s focus on licensing its technology to companies worldwide, this latest addition marks a significant milestone while highlighting its current growth trajectory, particularly as it continues to create value for its shareholders.

In addition, this milestone highlights the superiority of Lexaria’s DehydraTECH technology, as further compounded by the patents received so far and the pending patents worldwide. On August 29 and September 26, the company received its latest new patents in Canada, bringing the total number of granted patents to 37. Even so, Lexaria continues to invest heavily in its research and development (“R&D”), exploring the potential usage of its technology in various areas of application, including nicotine replacement, antivirals, cardiovascular drugs, human hormone delivery, CBD, PDE5 inhibitors and more.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN